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Objective:The clinical relationship between brain-derived neurotrophic factor (BDNF) and
cognitive function or mild cognitive impairment (MCI) is not well-understood. The purpose
of this study was to identify the relationship between serum BDNF and cognitive func-
tion and MCI, and determine whether serum BDNF level might be a useful biomarker for
assessing risk for MCI in older people.
Materials and Methods: A total of 4463 individuals aged 65 years or older (mean
age 72 years) participating in the study. We measured performance in a battery of
neuropsychological and cognitive function tests; serum BDNF concentration.
Results: Eight hundred twenty-seven participants (18.8%) had MCI. After adjustment for
sex, age, education level, diabetes, and current smoking, serum BDNF was associated with
poorer performance in the story memory, and digit symbol substitution task scores. Serum
BDNF was marginally associated with the presence of MCI (odds ratio, 95% confidence
interval: 1.41, 1.00–1.99) when BDNF was 1.5 SD lower than the mean value standardized
for sex and age, education level, diabetes, and current smoking.
Conclusion: Low serum BDNF was associated with lower cognitive test scores and MCI.
Future prospective studies should establish the discriminative value of serum BDNF for
the risk of MCI.
Keywords: brain-derived neurotrophic factor, cognition, biomarker, dementia, aged
INTRODUCTION
Mild cognitive impairment (MCI) is a transitional condition
between normal cognitive function and a clinical diagnosis of
probable Alzheimer’s disease (AD). MCI, including amnestic MCI,
is a pathologically heterogeneous disorder in which many persons
exhibiting mixed pathologies (Schneider et al., 2009). Few stud-
ies have investigated biomarkers for MCI. Most work has focused
on tau and/or Aβ-42 and their association with neuroimaging
results and clinical symptoms in persons at risk for AD. Biomark-
ers for AD and MCI must be established and validated in larger
cohorts, and efforts should be made to investigate markers of
other aspects of tau and Aβ pathology, including inflammation
and trophic factors (Winblad et al., 2004). Neuronal hypertrophy
might constitute an early cellular response to AD pathology or
reflect a compensatory mechanism that prevents cognitive impair-
ment despite substantial AD lesions (Riudavets et al., 2007; Iacono
et al., 2008, 2009). Neuronal cell growth is modulated by factors
such as brain-derived neurotrophic factor (BDNF) (Schindowski
et al., 2008). BDNF is highly concentrated in the hippocampus
(Phillips et al., 1990), important in synaptic plasticity (Kang and
Schuman, 1995; Figurov et al., 1996), and contributes to neuroge-
nesis in the dentate gyrus (Takahashi et al., 1999). BDNF plays a
pivotal role in age-related memory impairments and is associated
with age-related atrophy of the hippocampus. Previous studies
have reported that serum BDNF levels are reduced in AD (Gezen-
Ak et al., 2013), MCI (Peng et al., 2005; Yu et al., 2008), major
depression disorder, and depressive symptoms (Karege et al., 2002;
Shimizu et al., 2003; Cunha et al., 2006; Terracciano et al., 2011). A
study of neuronal cell cultures found that amyloid peptide at sub-
lethal concentrations interfered with neuronal plasticity mediated
by BDNF signaling cascade (Tong et al., 2004; Wang et al., 2006).
Neuronally differentiated P19 mouse embryonic carcinoma cells
stimulated by BDNF showed a rapid decrease in tau phosphory-
lation (Elliott et al., 2005). However, clinical studies that report
lower serum BDNF levels are difficult to interpret because of lim-
ited knowledge of potential confounders and mixed results based
on patient’s age and sex (Bus et al., 2012). Therefore, there is no
normal distribution in serum BDNF level, and this may lead to
misinterpretation of BDNF levels in studies that used paramet-
ric testing with small sample sizes (Ziegenhorn et al., 2007). To
establish a cut-off value for serum BDNF is important for clinical
purposes, e.g., for helping to increase diagnostic sensitivity. The
purpose of this study was to examine the relationships between
serum BDNF level and MCI and evaluate whether serum BDNF
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level may be useful for assessing MCI risk in older adults using a
large sample cohort. We explored the relationship between serum
BDNF level and MCI, and various measures of cognitive function
in elderly adults.
MATERIALS AND METHODS
STUDY POPULATION
Our study assessed 5104 individuals who were enrolled in the Obu
study of health promotion for the elderly (OSHPE). Each individ-
ual was recruited from Obu, Japan, which is a residential suburb of
Nagoya. To be included in this study, each participant was 65 years
or older at the time of examination (2011 or 2012), resided in
Obu city, and had not participated in another study. We excluded
participants who had missing BDNF data and characteristics, diag-
nosed neurological disorders included stroke, Parkinson’s disease,
AD, and depression, certified long-term care insurance, or func-
tional decline of activities of daily living (ADL). Figure 1 shows
the flow of participants (Figure 1). Six hundred forty-one of the
5104 participants were excluded and 4463 older adults (range 65–
97 years) were included in this study. The data of 4463 individuals
were used to analyze in the present study. Informed consent was
obtained from all participants prior to their inclusion in the study,
and the Ethics Committee of the National Center for Geriatrics
and Gerontology approved the study protocol.
BDNF MEASUREMENT
Whole blood samples were collected from each patient by
venipuncture. To obtain serum, whole blood samples were allowed
to coagulate at room temperature (RT) for 30 min and then cen-
trifuged at RT for 15 min at 1000× g. The collected serum was
stored in polypropylene tubes at −80°C until assayed. BDNF
concentrations were quantitatively determined by enzyme-linked
immunosorbent assay (ELISA) using the DuoSet ELISA Devel-
opment Kit from R&D Systems (Minneapolis, MN, USA). Assays
were performed using a specific human BDNF antibody (Min-
neapolis, MN, USA); no significant cross reactivity or interference
was observed in this assay. Serum samples were diluted 1:50. Sam-
ple BDNF concentrations were then determined by non-linear
regression from the standard curves. Measurements were per-
formed in duplicate and averaged to give a value in picogram
per milliliter, which was then expressed in nanogram per milliliter
after correcting for sample dilution. “Low” and “High” concentra-
tion quality control pools were prepared by adding 10 or 100 ng
to 5 ml portions of human serum (Innovative Research, Novi, MI,
USA), giving nominal concentrations of 2 and 20 ng/ml, respec-
tively. The assays were performed by one laboratory (SRL Inc.,
Tokyo, Japan). The repeatability of the BDNF ELISA, as mea-
sured by intra-assay precision was 3.8%, and the reproducibility,
as measured by inter-assay precision, was 7.6%.
MCI CRITERIA AND COGNITIVE FUNCTION TESTS
We defined MCI based on previous studies (Hanninen et al.,
2002; Jungwirth et al., 2005; Yaffe et al., 2011), using the fol-
lowing criteria: (1) subjective memory complaints; (2) objective
cognitive impairment [indicated by an age-adjusted score at least
1.5 SD below the reference threshold of any of the tests, all of
which are commonly used for detailed neuropsychological assess-
ments] but no general cognitive impairment; (3) no evidence
of functional dependency (no need for supervision or external
help in performing daily activities); and (4) exclusion from the
clinical criteria for dementia. Screening for MCI included a stan-
dardized personal interview for collecting sociodemographic and
FIGURE 1 | Flow of participants. A total of 4463 participants >65 years of age were included in the study. BDNF levels were measured and the participants
were divided into those with higher or lower BDNF levels below 1.0 and 1.5 standard deviations from the mean age- and sex-adjusted BDNF value.
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lifestyle data, medical history, and functional status (ADL) data,
along with cognitive function testing using the mini-mental state
examination (MMSE) (Folstein et al., 1975) and the National Cen-
ter For Geriatrics And Gerontology-Functional Assessment Tool
(NCGG-FAT) (Makizako et al., 2012). Individuals who scored≤23
points on the MMSE were considered to have general cognitive
impairment (Anthony et al., 1982). The NCGG-FAT consists of
multidimensional cognitive tasks used to assess word-list memory
(delayed recall), story memory (delayed recognition), attention
and executive function (tablet version of the Trail Making Test –
Part A and B), processing speed (tablet version of the symbol digit
substitution test), and visuospatial skill (figure selection). The par-
ticipants were given 20–30 min to complete the battery of tests and
their associated tasks. High test–retest reliability and moderate-to-
high validity were previously confirmed in community-dwelling
older adults for all components of the NCGG-FAT (Makizako et al.,
2012). All tests used in this study had previously established stan-
dardized thresholds for the definition of cognitive impairment in
the corresponding domain (score <1.5 SD below the age-specific
mean) for a population-based OSHPE cohort of healthy older
adults.
POTENTIAL CORRELATES
Based on the review articles by Bus et al. (2011, 2012), Ziegen-
horn et al. (2007), Knaepen et al. (2010), and Plassman (2010), we
selected three demographic variables, one physiological variable,
two health status indicators, and three behavioral variables as pos-
sible confounding factors of the association between BDNF and
cognitive decline (Ziegenhorn et al., 2007; Knaepen et al., 2010; Bus
et al., 2011, 2012). The three demographic variables – sex, age, and
educational level – were selected as possible confounding factors
in determining the association of serum BDNF and MCI. Walking
speed – the physiological variable – was measured on a flat and
straight surface at a comfortable walking speed. Two markers were
used to indicate the start and end of a 2.4-m walkway, with a 2-m
section to traverse before passing the start marker so that partici-
pants were walking at a comfortable pace by the time they reached
the timed path. Participants were asked to continue walking for an
additional 2 m past the end of the path to ensure a consistent walk-
ing pace while on the timed path. Histories of heart disease and
diabetes were obtained as health status indicators. Behavioral fac-
tors, including current smoking, regular exercise, and frequency of
going outdoors, were identified during the interview. Participants
were asked whether they currently smoked or exercised regularly:
responses were either “yes” or “no.” Participants were asked how
often they traveled to places outside their town during a week.
STATISTICAL ANALYSIS
Student’s t -test was used to compare BDNF concentrations
between men and women. Differences in serum BDNF concen-
trations were analyzed among four age-groups (65–69, 70–74,
75–79, 80–84, and ≥85 years) by one-way analysis of variance
(ANOVA) in both sexes. A linear regression was used to analyze
the relationships between BDNF concentration and age and edu-
cation in both sexes. Participants were divided into two groups
according to 1.0 or 1.5 SD from age- and sex-specific mean val-
ues among the four age-groups (Figure 1). Independent sample
t -tests or Chi-square tests were used to compare the potential
correlates and cognitive performance between: (a) participants
who had BDNF levels below 1.0 SD and above 1.0 SD; and (b)
participants who had BDNF levels below 1.5 SD and above 1.5
SD. Linear regression analyses (forced-entry) were used to reveal
the relationships between BDNF concentration and cognitive per-
formance. Multivariate logistic regression analyses, forced-entry,
were used to determine adjusted odds ratios (ORs) and 95% confi-
dence intervals (95% CIs), and to assess independent associations
between the serum BDNF levels and MCI. The covariates of sex,
age, and educational level, and significant variables in univariate
analyses were added to the regression models to evaluate indepen-
dent associations between BDNF and cognitive performances or
MCI. Logistic regression models determined the crude OR and
the adjusted OR of BDNF for 1.0 and 1.5 SD. Sensitivity, speci-
ficity, and positive and negative likelihood ratios of the BDNF
values with MCI were calculated. We excluded the participants
who scored ≤23 points on the MMSE and did not complain of
memory loss. We used the data of MCI (n= 827) and cognitive
healthy (n= 2533) elderly adults in the logistic regression analyses.
All statistical comparisons were made at the 0.05 level of signifi-
cance, and all data management and statistical computations were
performed using the IBM SPSS Statistics 20.0 software package
(SPSS Inc., Chicago, IL, USA).
RESULTS
The mean BDNF concentrations were statistically significantly dif-
ferent in men (20.8± 5.6 ng/ml) and women (21.2± 5.2 ng/ml;
t = 2.162, df= 4394, P = 0.031). BDNF concentrations declined
with increasing age in both sexes (F = 24.822, df= 3, P < 0.001)
(Table 1; Figure 2). Linear regression found that serum BDNF was
Table 1 | Serum BDNF levels among the four age-groups.
Men Women
BDNF values 1.0 SD
lower than the mean
BDNF values 1.5 SD
lower than the mean
BDNF values 1.0 SD
lower than the mean
BDNF values 1.5 SD
lower than the mean
65–69 years 16.08 13.34 16.75 14.15
70–74 years 15.20 12.52 15.85 13.16
75–79 years 14.82 11.84 15.12 12.57
80 years and over 13.30 10.27 15.05 12.63
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associated with age in men (β=−0.123, t =−5.750, P < 0.001)
and women (β=−0.154, t =−7.475, P < 0.001). Education
level was associated with serum BDNF in women (β= 0.045,
t = 2.149, P = 0.032), but not in men (β= 0.012, t = 0.564,
P = 0.573).
The comparison between participants who had BDNF lev-
els below 1.0 SD and above 1.0 SD, revealed that the partic-
ipants below 1.0 SD had a higher prevalence of diabetes, a
FIGURE 2 | Sex and age differences in serum BDNF concentration.
Mean and standard error of serum BDNF levels are shown for each 5-year
increment in age. Serum BDNF decreased with aging in men (black bars)
and women (white bars; P <0.001) and women showed higher BDNF
levels than men (P =0.031).
lower proportion of smokers, higher scores of story memory,
and a symbol digit substitution task, compared with partici-
pants who had BDNF levels above 1.0 SD. The results were
similar for the comparison between the participants who had
BDNF levels below 1.5 SD and above 1.5 SD. A comparison
of MCI prevalence found no significant difference between the
participants who had serum BDNF below and above 1.0 SD. In
contrast, when serum BDNF was dichotomized according to 1.5
SD below the mean, a significant difference was found in MCI
(Table 2). The mean BDNF concentrations did not show sig-
nificant differences between MCI participants (20.9± 5.3 ng/ml)
and non-MCI participants (21.2± 5.4 ng/ml; t = 1.362,df= 3358,
P = 0.173).
Table 3 shows the association between serum BDNF and per-
formance on various cognitive function tests using multiple linear
regression, adjusted for sex, age, education level, diabetes, and cur-
rent smoking status. Serum BDNF levels were associated with a
decline in story memory (β= 0.027, t = 1.958,P < 0.05) and digit
symbol substitution test scores (β= 0.027, t = 2.172, P < 0.05).
There was no significance between BDNF and MMSE for word-
list memory, the tablet version of the Trail Making Test – Part A
and B, or figure selection.
In all, 827 participants (18.8%) had MCI. A total of 691 partic-
ipants (15.5%) had BDNF levels below 1.0 SD from the mean, and
246 participants (5.5%) had levels below 1.5 SD from the mean.
Table 4 shows the association between serum BDNF levels and
the diagnosis of MCI using multiple logistic regression, adjusted
for sex, age, education level, diabetes, and current smoking sta-
tus. The crude logistic model showed significant relationships
between MCI and BDNF: 1.5 SD (OR, 1.40; 95% CI, 1.00–1.96),
Table 2 | Comparisons between BDNF levels of 1.0 and 1.5 SD from the mean.
BDNF levels of 1.0 SD from the mean BDNF levels of 1.5 SD from the mean
Participants
above 1.0 SD
Participants
below 1.0 SD
P Participants
above 1.0 SD
Participants
below 1.0 SD
P
Sex, women, n, % 1919, 50.9 372, 53.8 0.152 2175, 51.6 116, 47.2 0.177
Age, years 71.9±5.4 72.1±5.5 0.395 71.9±5.5 71.8±5.2 0.744
Education level, years, 10a 11.4±2.5 11.3±2.5 0.294 11.4±2.5 11.2±2.5 0.237
Walking speed, m/s, 6a 1.3±0.2 1.3±0.2 0.236 1.3±0.2 1.3±0.2 0.722
Heart disease, yes, n, 2a 585, 15.5 124, 17.9 0.109 671, 15.9 38, 15.4 0.844
Diabetes, yes, n 474, 12.6 111, 16.1 0.012 538, 12.8 47, 19.1 0.004
Current smoking, yes, n, %, 1a 392, 10.4 51, 7.4 0.015 430, 10.2 13, 5.3 0.012
Habitual exercise, yes, n, 5a 2816, 74.8 519, 75.1 0.844 3152, 74.8 183, 74.4 0.876
Going outdoors, times/week, 1a 5.9±1.6 5.8±1.7 0.125 5.9±1.7 5.8±1.7 0.841
MMSE score, 6a 26.3±2.7 26.2±2.8 0.64 26.3±2.7 26.0±2.8 0.09
Word-list memory score, 19a 3.8±2.0 3.8±2.0 0.872 3.8±2.0 3.7±2.0 0.466
Story memory score, 26a 6.8±1.9 6.6±1.9 0.029 6.7±1.9 6.4±1.9 0.011
Trail making test – part A, s, 11a 21.2±6.9 21.5±7.3 0.261 21.2±7.0 22.0±7.1 0.083
Trail making test – part B, s, 15a 43.1±17.9 44.1±18.4 0.173 43.2±17.9 45.3±18.7 0.068
Symbol digit substitution task, 14a 38.4±8.4 37.5±8.5 0.013 38.3±8.4 37.2±8.4 0.049
Visuospatial skill score, 85a 5.2±1.5 5.2±1.5 0.928 5.2±1.5 5.2±1.4 0.798
Mild cognitive impairment, yes, n, %, 73a 689, 24.2 138, 24.6 0.244 774, 24.3 53, 31.0 0.047
aNumber of missing data.
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Table 3 | Multiple linier regression analyses with serum BDNF, potential confounders, and cognitive tests.
Independent
variable
Dependent variables
MMSE Word-list
memory
Story
memory
Trail making
test – part A
Trail making
test – part B
Symbol digit
substitution task
Visuospatial
skill
β P β P β P β P β P β P β P
BDNF, ng/ml 0.011 0.442 0.017 0.229 0.027 0.050 −0.008 0.584 −0.022 0.091 0.027 0.030 −0.011 0.472
Sex, men=1,
women=2
0.156 <0.001 0.160 <0.001 0.107 <0.001 −0.032 0.027 −0.027 0.050 −0.028 0.030 −0.074 <0.001
Age, years −0.208 <0.001 −0.316 <0.001 −0.322 <0.001 0.354 <0.001 0.400 <0.001 −0.473 <0.001 −0.167 <0.001
Education, years 0.219 <0.001 0.176 <0.001 0.242 <0.001 −0.167 <0.001 −0.235 <0.001 0.230 <0.001 0.192 <0.001
Diabetes, no=1,
yes=2
0.009 0.512 −0.016 0.253 −0.015 0.254 0.023 0.091 0.006 0.616 −0.036 0.003 −0.015 0.306
Current smoking,
no=1, yes=2
−0.042 0.004 −0.009 0.522 0.004 0.781 0.031 0.029 0.057 <0.001 −0.059 <0.001 0.012 0.421
Table 4 | Relationships between MCI and BDNF or selected correlates.
Crude OR Adjusted OR in
BDNF 1.0 SD
Adjusted OR in
BDNF 1.5 SD
OR (95% CI) P OR (95% CI) P OR (95% CI) P
BDNF 1.0 SD, below/above 1.14 (0.92–1.40) 0.244 1.14 (0.92–1.42) 0.236
BDNF 1.5 SD, below/above 1.40 (1.00–1.96) 0.048 1.41 (1.00–1.98) 0.050
Sex, women/men 1.00 (0.86–1.17) 0.971 0.85 (0.71–1.00) 0.051 0.85 (0.72–1.01) 0.063
Age, years 1.02 (1.01–1.04) 0.003 1.00 (0.99–1.02) 0.977 1.00 (0.99–1.02) 0.942
Education, years 0.82 (0.79–0.85) <0.001 0.82 (0.79–0.85) <0.001 0.82 (0.79–0.85) <0.001
Diabetes, yes/no 1.11 (0.88–1.39) 0.377 1.04 (0.82–1.31) 0.752 1.03 (0.82–1.31) 0.778
Current smoking, yes/no 1.09 (0.84–1.43) 0.517 1.19 (0.90–1.59) 0.23 1.20 (0.90–1.60) 0.208
age (OR, 1.02; 95% CI, 1.01–1.04), and education (OR, 0.82;
95% CI, 0.79–0.85). The adjusted logistic model for BDNF 1.0
SD showed no significant relationship between serum BDNF and
MCI. In contrast, when serum BDNF was dichotomized accord-
ing to 1.5 SD below the mean, a significant association with
MCI was found (OR, 1.41; 95% CI, 1.00–1.98). Education was
also associated with MCI (OR, 0.82; 95% CI, 0.79–0.85). Sensi-
tivity and specificity of the BDNF values for 1.5 SD were 6.4%
(95% CI: 4.8–8.3%) and 95.3% (95% CI: 94.5–96.1%), respec-
tively. Positive and negative likelihood ratios of the BDNF values
of 1.5 SD were 1.38 (95% CI: 1.00–1.88) and 0.98 (0.96–1.00),
respectively.
DISCUSSION
In our cross-sectional observational study of 4463 community-
living older adults, serum BDNF was associated with a decline in
story memory and digit symbol substitution test scores, even when
adjusted for sex, age, education, diabetes, and current smoking.
Moreover, serum BDNF levels of 1.5 SD lower than the age- and
sex-adjusted means were associated with a significant risk of MCI.
These results suggest that serum BDNF may be a useful biomarker
of cognitive function and MCI status in the elderly.
In demographic variables, serum BDNF was higher in women
than men. Similar results were found by Trajkovska et al. (2007)
using both serum and whole blood BDNF, whereas they were in
contrast to other studies using only serum BDNF (Lang et al.,
2004; Ziegenhorn et al., 2007). Another study found a significant
interaction of age and menopausal state with BDNF in women,
with age-related increases serum BDNF premenopause and age-
related decreases postmenopause (Bus et al., 2011). Estrogen levels
are significantly associated with BDNF levels (Scharfman and
MacLusky, 2006), so the postmenopausal drop in estrogen could
result in decreased serum BDNF. Therefore, the differences in
serum BDNF levels in men and women might be related to sex hor-
mone differences. However, it is difficult to draw conclusions with
cross-sectional approaches, and longitudinal studies are needed.
Among lifestyle measures, diabetes and current smoking
showed significant differences between the participants who
had high and low serum BDNF levels. Low levels of BDNF
accompanied impaired glucose metabolism. Krabbe et al. reported
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that plasma levels of BDNF were decreased in participants with
type 2 diabetes independent of obesity (Krabbe et al., 2007).
Plasma BDNF was inversely associated with fasting plasma glucose,
but not with insulin. When plasma insulin was increased while
maintaining normal blood glucose, the cerebral output of BDNF
was not inhibited, indicating that high levels of glucose, but not
insulin, inhibit the output of BDNF from the human brain. They
concluded that the cerebral output of BDNF, which is negatively
related to high plasma glucose levels and decreased BDNF, may be
a pathogenetic factor involved not only in dementia, but also in
type 2 diabetes. The results of our cohort support previous find-
ings. Smoking was associated with higher BDNF levels; this finding
is consistent with several studies. In animal studies, regional brain
BDNF expression was altered by exposure to or withdrawal from
nicotine (Kenny et al., 2000). In some human studies, smoking
cessation increased BDNF serum levels over the span of several
months (Kim et al., 2007; Bhang et al., 2010). A recent epidemi-
ological study of 1168 subjects aged 18–65 years also reported an
independent relationship between smoking and serum BDNF lev-
els, with higher BDNF in former and current smokers compared
to subjects who never smoked (Bus et al., 2011). The results of
our study confirm this relationship between BDNF and smoking
in adults 65 years of age and older. Nicotine has induced SH-SY5Y
neuroblastoma cell proliferation through BDNF and its receptor,
TrkB. The activation of nicotinic receptors has effects upon the
BDNF–TrkB pathway, inducing cell proliferation by promoting
the release of BDNF, which in turn activates TrkB receptors (Ser-
res and Carney, 2006). Moreover, the beta-arrestin-2 protein is
important in induction and expression of nicotine sensitization as
well as nicotine’s effects on accumbal BDNF (Correll et al., 2009).
Brain-derived neurotrophic factor is highly concentrated in
the hippocampus (Phillips et al., 1990; Wetmore et al., 1990). A
single nucleotide polymorphism in the BDNF gene affects the
regulated secretion of BDNF in the hippocampus (Egan et al.,
2003) and has been related to lower serum levels of BDNF (Ozan
et al., 2010) and smaller hippocampal volumes (Pezawas et al.,
2004; Szeszko et al., 2005), which can lead to deficits in execu-
tive function (Frodl et al., 2006) and memory function (Erickson
et al., 2009). The hippocampus–orbitomedial prefrontal circuit
integrates cognition, emotion, and behavior, thereby influenc-
ing working memory and executive functions (Wall and Messier,
2001). The observed relationship between lower serum BDNF and
impaired memory and processing speed is consistent with previ-
ous studies. However, the relationships between serum BDNF and
executive function, the Trail Making Test – Part B, did not reach
significance (P = 0.09). Further studies will be needed to establish
the relationships between serum BDNF and executive function in
the elderly adults.
Serum BDNF values 1.5 SD lower than the age- and sex-
adjusted mean were associated with MCI, whereas serum BDNF
levels lower than 1.0 SD from age- and sex-adjusted mean serum
BDNF values were not. These results suggest that the partici-
pants who had 1.5 SD lower than the mean age- and sex-adjusted
BDNF values may pose a risk of cognitive impairment. BDNF sup-
ports cholinergic, dopaminergic, serotonergic, and neuropeptide-
containing neurons (Hyman et al., 1991; Knusel et al., 1991;
Mamounas et al., 1995) and may play an important role in
AD-related pathophysiology. Animal studies found that Aβ dis-
rupts BDNF signaling and that BDNF protects against Aβ toxicity
via TrkB signaling (Tapia-Arancibia et al., 2008). Lower levels of
both BDNF and TrkB have been found in postmortem brains of
individuals with AD (Murer et al., 2001). BDNF levels are sig-
nificantly reduced in the hippocampus and parietal cortex and
BDNF/neurotrophin 3 ratios are lower in frontal and parietal cor-
tices in patients with AD compared with age-matched controls
(Hock et al., 2000). Higher serum levels of BDNF in individuals
with AD are predictive of slower rates of decline (Laske et al., 2011).
Peng et al. (2005) reported strong relationships between MMSE
and Global Cognitive Score results and proBDNF and mature
BDNF levels. Decreased serum BDNF in the preclinical stages of
AD further suggests that BDNF and proBDNF deficiency play a
pivotal role in cell atrophy, cell loss, and synaptic dysfunction,
with a lack of trophic support contributing to the degeneration of
specific neuronal subpopulations in the AD-affected brain (Hock
et al., 2000; Laske et al., 2007).
Other studies have shown that BDNF serum levels increase
in MCI and AD patients (Angelucci et al., 2010). This increase
may reflect a compensatory repair mechanism in early and late
neurodegeneration that is protective by contributing to Aβ degra-
dation. Laske et al. (2006) found that patients in the early stages of
probable AD with MMSE scores ≥21 (mean of 25.5) had signifi-
cantly higher serum BDNF levels compared to patients in late-stage
AD with MMSE scores <21 (mean of 13.3) and age-matched
healthy controls. The study also showed a tendency toward lower
BDNF levels in patients with late-stage AD and progressive demen-
tia (mean MMSE: 13.3; range: 6–20). The mean MMSE scores of
our MCI participants was 26.6 (range: 24–30), higher than that of
patients in the early stages of probable AD in the Laske et al. (2006)
study. Our MCI participants may have been at a stage earlier than
the point at which the BDNF compensatory repair mechanism is
triggered in early neurodegeneration.
The strengths of the present study include the large sample size
and comprehensive measurement of cognitive function, which
correlates closely with dementia. One limitation of the study is
that the analysis is based on cross-sectional data. Although our
study was population-based, further prospective investigations are
needed to validate using 1.5 SD serum BDNF levels for discrim-
inating the risk of cognitive decline and MCI in older people.
Sensitivity of the 1.5 SD serum BDNF levels to discriminate MCI
and healthy participants showed a very low value (6.4%). The
result suggests that it is necessary to review the discrimination
point to screen MCI in the community with high sensitivity.
BDNF is reduced in elderly individuals with major depression
and bipolar disorder, with distinct dynamics according to the dis-
ease stages, treatment, or the presence of cognitive impairment
(Molendijk et al., 2011; McKinney and Sibille, 2013; Sibille, 2013).
In a recently published study, Diniz et al. (2014) showed a sig-
nificant decline in serum BDNF level over 2 years of follow-up
only in those individuals with persistent cognitive decline (Diniz
et al., 2014). Therefore, BDNF seems to be a non-specific marker
for many neuropsychiatric disorders, thus, reducing its discrim-
inative power to identify individuals with MCI. Our study also
excluded older adults with neurological disorders and those adults
who were certified for long-term care insurance due to functional
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decline. Therefore, the study findings may not be generalized to
these patient groups. It is likely that several clinical and etiological
heterogeneities exist between subtypes of MCI (Petersen, 2004).
Although amnestic MCI appears to be most closely linked with
AD, there are many concomitant pathologic abnormalities, includ-
ing argyrophilic grain disease, hippocampal sclerosis, and vascular
lesions (Petersen et al., 2006). The findings of the study about
the relationships between serum BDNF and MCI may change in
further analyses of each subtype of MCI.
In conclusion, we provide preliminary evidence that serum
BDNF can be associated with lower cognitive test scores in older
people. In our cohort, serum BDNF was marginally associated
with the presence of MCI when BDNF was 1.5 SD lower than
the mean age- and sex-adjusted values. Future prospective stud-
ies should establish the discriminative value of serum BDNF
for a risk of MCI and its validity as a screening test for this
population.
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